Objective: To determine the association between indomethacin tocolysis and
neonatal intraventricular hemorrhage.
Methods: Fifty-six preterm neonates with intraventricular hemorrhage were m
atched by gestational age with neonates (n = 224) without this morbidity. M
aternal and neonatal charts were reviewed to ascertain the type of tocolyti
c exposure experienced by the neonate. Other maternal and neonatal demograp
hic and outcome data were also abstracted. Results were analyzed using the
Student t test, chi (2) analysis, and multivariable logistic regression. Th
e number of studied subjects provided 80% power to determine if antenatal e
xposure to indomethacin was twice as likely among infants with intraventric
ular hemorrhage.
Results: Univariate analysis revealed that there were no significant differ
ences between the study and control groups with respect to maternal age, pa
rity, or betamethasone exposure. Infants with intraventricular hemorrhage w
ere significantly more likely to be born at an earlier gestational age, a l
ower birth weight, after maternal chorioamnionitis, after vaginal delivery,
and after exposure to either indomethacin alone or a combination of indome
thacin and magnesium. Additionally, their neonatal course was significantly
more likely to be complicated by sepsis and respiratory distress syndrome.
In a multivariable logistic model, only gestational age, chorioamnionitis,
vaginal delivery, and respiratory distress syndrome continued to be signif
icantly associated with intraventricular hemorrhage. Indomethacin exposure,
either as single-agent (adjusted odds ratio 1.3, 95% confidence interval 0
.5, 3.3) or combination tocolytic therapy (adjusted odds ratio 2.0, 95% con
fidence interval 0.8, 4.8), was not significantly associated with intravent
ricular hemorrhage.
Conclusion: Indomethacin tocolysis is not associated with an increased risk
of intraventricular hemorrhage. (Obstet Gynecol 2001;97:921-5. (C) 2000 by
The American College of Obstetricians and Gynecologists.).